Growth Factor News and Research

RSS

Calorie restriction may help people to lead longer and healthier lives

Organisms from yeast to rodents to humans all benefit from cutting calories. In less complex organisms, restricting calories can double or even triple lifespan. It's not yet clear just how much longer calorie restriction might help humans live, but those who practice the strict diet hope to survive past 100 years old.

16 Apr 2010

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.

16 Apr 2010

New research identifies cellular channel that regulates skin and hair growth

Skin and hair follicles are constantly renewed in the body, maintained by specialized stem cells. New research from Children's Hospital Boston identifies a small cellular channel that regulates skin and hair growth and that could be targeted with small-molecule drugs, potentially treating variety of skin conditions, as well as thinning hair or unwanted hair growth. Findings appear in the April 16, 2010 issue of Cell.

16 Apr 2010

Research team to receive AACR Team Science Award

The fourth annual American Association for Cancer Research Team Science Award will be given to Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team at the AACR 101st Annual Meeting 2010. This research team is comprised of interdisciplinary investigators from the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and Harvard Medical School.

15 Apr 2010

Omega-3 fatty acids improve nerve regeneration, prevent psychotic disorders and reduce cellular aging

Improving nerve regeneration after corneal surgery, preventing psychotic disorders in those at high risk for them and reducing cellular aging are three emerging benefits of the omega-3 fatty acids found in seafood, according to milestone research described in the April 2010 PUFA Newsletter and Fats of Life online publications for health professionals and consumers, respectively.

9 Apr 2010

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.

8 Apr 2010

Researchers develop new mouse model of VUR to study chronic kidney disease in children

Kidney damage associated with chronic reflux is the fourth leading cause of chronic kidney disease and is the most common cause of severe hypertension in children. Doctors and researchers at Nationwide Children's Hospital have developed a new mouse model of vesicoureteral reflux, a common childhood condition that can lead to chronic kidney disease in children.

7 Apr 2010

Researchers commence Phase 2 research study to test CERE-110 for AD

Researchers at Banner Sun Health Research Institute are about to start the first Phase 2 research study to test a gene transfer agent for Alzheimer's disease. AD is a degenerative and ultimately fatal disorder affecting as many as five million Americans and that number is expected to soar to more than 11 million by 2040.

7 Apr 2010

Cancer research at Georgia Tech: Report

Cancer treatment typically involves surgery, radiation therapy, chemotherapy, hormone therapy or biological therapy. An oncologist may use one therapy or a combination of methods, depending on the type and location of the cancer, whether the disease has spread, the patient's age and general health, and other factors.

3 Apr 2010

Cancer Prevention Coalition submits petition on imminent health hazard from hormonal meat

As reported in a March 18, New York Times editorial, "Honest Food Labels," FDA Commissioner, Margaret Hamburg, M.D., publicized letters to 17 food companies accusing them of -- "masking undesirable ingredients" -- in their products. She also emphasized the importance of "providing nutrition information that consumers can rely on."

3 Apr 2010

Study finds potential role of NGF in islet transplantation

Islet transplantation is a promising treatment for type 1 diabetes mellitus. The promotion of angiogenesis is an important endeavor to prevent islet graft failure. Endothelial precursor cells (EPCs), a heterogeneous group originating in the hematopoietic compartment of bone marrow, have an important role in the angiogenesis of adult tissues.

2 Apr 2010

Gene therapy improve survival rates among heart attack patients

Gene therapy could be an effective way to improve survival rates among heart attack patients, new research funded by the British Heart Foundation (BHF) suggests. Academics at the University of Bristol found that boosting levels of a natural growth factor in the heart could help the muscle to recover after a heart attack. The death rate from a heart attack was halved in mice that received the treatment.

1 Apr 2010

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.

1 Apr 2010

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ArQule, Inc. today announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival in patients with advanced, refractory non-small cell lung cancer.

31 Mar 2010

USPTO issues Notice of Allowance for menadione to prevent skin rash in patients taking EGFR inhibitors

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for the use of menadione to prevent and treat skin rash in patients taking biologic and small molecule epidermal growth factor receptor inhibitors, such as Erbitux® and Tarceva®, for anti-cancer therapy.

31 Mar 2010

Researchers find Dpp protein causes metastatic tumour migration

One of the most intriguing questions in cancer research is what causes metastatic tumour migration, why some tumour cells manage to migrate to other parts of the body but others cells don't. International investigation conducted by Enrique Mart-n Blanco, CSIC researcher at the Institute of Biology of Barcelona, located in the Barcelona Science Park, reveals that cells make use of a natural mechanism for this.

30 Mar 2010

Gene expression in breast tissue may help explain pregnancy-associated breast cancer

Expression of inflammatory-related genes in breast tissue of women who have previously given birth may explain the aggressiveness and frequency of pregnancy-associated breast cancer, according to new research at the University of Illinois at Chicago.

30 Mar 2010

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

29 Mar 2010

Survival improving in patients with HER2 positive metastatic breast cancer

Barcelona, Spain: Trends indicate that survival is improving in patients with metastatic breast cancer, especially in those patients whose tumours are described as being HER2 (human epidermal growth factor receptor-2) positive, a surgical oncologist will say today at the seventh European Breast Cancer Conference (EBCC7).

26 Mar 2010

Survival rate is improving in HER2 positive breast cancer patients

Trends indicate that survival is improving in patients with metastatic breast cancer, especially in those patients whose tumours are described as being HER2 (human epidermal growth factor receptor-2) positive, a surgical oncologist will say today (Friday 26 March) at the seventh European Breast Cancer Conference.

26 Mar 2010